

BIOCON GROUP

FACT SHEET

March - 2020

BIOCON LIMITED (CONSOLIDATED)		
BALANCE SHEET		
	(Rs Cr)	
	March 31, 2020	March 31, 2019
ASSETS		
Non-current assets		
(a) Property, plant and equipment	5,393	4,253
(b) Capital work-in-progress	1,577	1,287
(c) Right-of-use assets	128	-
(d) Goodwill	26	26
(e) Other intangible assets	423	192
(f) Intangible assets under development	620	612
(g) Investments in associates and a joint venture	14	43
(h) Financial assets		
Investments	94	139
Derivative assets	26	71
Other financial assets	56	39
(i) Income-tax asset, net	242	169
(j) Deferred tax asset, net	368	325
(k) Other non-current assets	151	147
	9,119	7,304
Current assets		
(a) Inventories	1,436	1,032
(b) Financial assets		
Investments	858	829
Trade receivables	1,224	1,292
Cash and cash equivalents	910	730
Other bank balances	89	327
Derivative assets	19	78
Other financial assets	450	387
(c) Other current assets	340	215
	5,325	4,889
TOTAL	14,444	12,192
EQUITY AND LIABILITIES		
Equity		
(a) Equity share capital	600	300
(b) Other equity	6,106	5,798
Equity attributable to owners of the Company	6,706	6,098
Non-controlling interests	677	609
	7,383	6,707
Non-current liabilities		
(a) Financial liabilities		
Borrowings	1,222	1,526
Lease liabilities	83	15
Derivative liability	146	35
Other financial liabilities	536	-
(b) Provisions	86	66
(c) Deferred tax liability, net	30	-
(d) Other non-current liabilities	949	805
	3,053	2,447
Current liabilities		
(a) Financial liabilities		
Borrowings	668	261
Lease liabilities	7	1
Trade payables	1,325	1,198
Derivative liability	72	14
Other financial liabilities	1,208	991
(b) Provisions	103	81
(c) Income tax liability, net	128	124
(d) Other current liabilities	498	369
	4,008	3,039
TOTAL	14,444	12,192

BIOCON LIMITED (CONSOLIDATED)			
PROFIT & LOSS STATEMENT			(Rs. Crores)
Particulars	FY 2020	FY 2019	Variance
<u>INCOME</u>			
Small molecules	2,094	1,773	18%
Biologics	1,951	1,517	29%
Branded formulations	536	656	-18%
Research services	2,012	1,826	10%
Inter-segment	(226)	(257)	-12%
Revenue from operations #	6,367	5,514	15%
Other income	161	144	12%
TOTAL REVENUE	6,529	5,659	15%
<u>EXPENDITURE</u>			
Material & Power costs	2,299	2,136	8%
Staff costs	1,328	1,062	25%
Research & Development expenses*	439	290	52%
Other expenses	698	633	10%
Manufacturing, staff & other expenses	4,764	4,121	16%
EBITDA	1,765	1,538	15%
Interest & Finance charges	65	71	-8%
Depreciation & Amortisation	552	448	23%
Share of loss / (profit) in JV / Associate, net	29	(1)	-3311%
PBT BEFORE EXCEPTIONAL ITEM	1,119	1,020	10%
Exceptional item, Net	68	195	-
PBT	1,186	1,215	-2%
Taxes	250	194	29%
Taxes on exceptional item	66	18	-
NET PROFIT BEFORE MINORITY INTEREST	871	1,003	-13%
Minority interest	109	97	12%
Minority interest on exceptional item	14	-	-
NET PROFIT FOR THE PERIOD	748	905	-17%
EPS Rs.	6.2	7.5	
NET PROFIT BEFORE EXCEPTIONAL ITEM			
	760	729	4%
Exceptional item, net of taxes	(12)	176	
NET PROFIT FOR THE PERIOD	748	905	-17%
<i>Note: The figures are rounded off to the nearest crores, percentages are based on absolute numbers</i>			
# Licensing Income	31	25	
* Gross Research & Development expenses	527	480	

BIOCON LIMITED (CONSOLIDATED)			
PROFIT & LOSS STATEMENT			(Rs. Crores)
Particulars	Q4 FY 20	Q4 FY 19	Variance
INCOME			
Small molecules	541	472	15%
Biologics	357	451	-21%
Branded formulations	117	133	-12%
Research services	607	534	14%
Inter-segment	(42)	(61)	-32%
Revenue from operations #	1,581	1,529	3%
Other income	63	28	124%
TOTAL REVENUE	1,644	1,557	6%
EXPENDITURE			
Material & Power costs	623	549	14%
Staff costs	354	293	21%
Research & Development expenses*	125	92	36%
Other expenses	160	193	-17%
Manufacturing, staff & other expenses	1,262	1,126	12%
EBITDA	382	431	-11%
Interest & Finance charges	17	16	6%
Depreciation & Amortisation	152	120	27%
Share of loss / (profit) in JV / Associate, net	8	11	-25%
PBT BEFORE EXCEPTIONAL ITEM	204	284	-28%
Exceptional item, Net	-	-	
PBT	204	284	-28%
Taxes	45	41	10%
Taxes on exceptional item	-	-	-
NET PROFIT BEFORE MINORITY INTEREST	159	243	-35%
Minority interest	36	30	20%
NET PROFIT FOR THE PERIOD	123	214	-42%
EPS Rs.	1.0	1.8	
NET PROFIT BEFORE EXCEPTIONAL ITEM			
	123	214	-42%
Exceptional item, net of taxes	-	-	
NET PROFIT FOR THE PERIOD	123	214	-42%
<i>Note: The figures are rounded off to the nearest crores, percentages are based on absolute numbers</i>			
# Licensing Income	8	7	
* Gross Research & Development expenses	139	166	

BIOCON LIMITED (CONSOLIDATED)			
PROFIT & LOSS STATEMENT			(Rs. Crores)
Particulars	Q4 FY 20	Q3 FY 20	Variance
INCOME			
Small molecules	541	544	-1%
Biologics	357	588	-39%
Branded formulations	117	157	-25%
Research services	607	519	17%
Inter-segment	(42)	(60)	-31%
Revenue from operations #	1,581	1,748	-10%
Other income	63	36	76%
TOTAL REVENUE	1,644	1,784	-8%
EXPENDITURE			
Material & Power costs	623	636	-2%
Staff costs	354	342	4%
Research & Development expenses*	125	131	-5%
Other expenses	160	194	-18%
Manufacturing, staff & other expenses	1,262	1,304	-3%
EBITDA	382	480	-20%
Interest & Finance charges	17	18	-5%
Depreciation & Amortisation	152	144	6%
Share of profit in JV / Associate, net	8	3	163%
PBT BEFORE EXCEPTIONAL ITEM	204	315	-35%
Exceptional item, Net	-	-	-
PBT	204	315	-35%
Taxes	45	63	-28%
Taxes on exceptional item	-	22	-100%
NET PROFIT BEFORE MINORITY INTEREST	159	230	-31%
Minority interest	36	28	30%
Minority interest on exceptional item	-	-	-
NET PROFIT FOR THE PERIOD	123	203	-39%
EPS Rs.	1.0	1.7	
NET PROFIT BEFORE EXCEPTIONAL ITEM			
	123	225	-45%
Exceptional item, net of taxes	-	(22)	
NET PROFIT FOR THE PERIOD	123	203	-39%
<i>Note: The figures are rounded off to the nearest crores, percentages are based on absolute numbers</i>			
# Licensing Income	8	9	
* Gross Research & Development expenses	139	155	